Protagonist Therapeutics, Inc. (PTGX): Price and Financial Metrics

Protagonist Therapeutics, Inc. (PTGX): $26.11

0.47 (-1.77%)

POWR Rating

Component Grades








Add PTGX to Watchlist
Sign Up

PTGX Price/Volume Stats

Current price $26.11 52-week high $33.34
Prev. close $26.58 52-week low $13.72
Day low $25.93 Volume 524,106
Day high $26.40 Avg. volume 721,230
50-day MA $28.45 Dividend yield N/A
200-day MA $21.72 Market Cap 1.52B

PTGX Stock Price Chart Interactive Chart >

Protagonist Therapeutics, Inc. (PTGX) Company Bio

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded in 2006 and is based in Milpitas, California.

PTGX Latest News Stream

Event/Time News Detail
Loading, please wait...

PTGX Latest Social Stream

Loading social stream, please wait...

View Full PTGX Social Stream

Latest PTGX News From Around the Web

Below are the latest news stories about PROTAGONIST THERAPEUTICS INC that investors may wish to consider to help them evaluate PTGX as an investment opportunity.

Insider Sell Alert: CEO PATEL DINESH V PH D Sells 75,000 Shares of Protagonist Therapeutics Inc ...

In a notable insider transaction, President and CEO PATEL DINESH V PH D has sold 75,000 shares of Protagonist Therapeutics Inc (NASDAQ:PTGX), a clinical-stage biopharmaceutical company.

Yahoo | December 16, 2023

Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis

NEWARK, CA / ACCESSWIRE / December 13, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced it has earned a $10 million milestone payment following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to ...

Yahoo | December 13, 2023

Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals

Long term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia veraAnalysis of PACIFIC Phase 2 study shows that rusfertide improves ...

Yahoo | December 12, 2023

Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib

The ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or IGA 0 or 1Protagonist eligible to receive $115 million milestone upon achieving the co-primary endpoints in any ...

Yahoo | November 27, 2023

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESSWIRE / November 16, 2023 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on November 15, 2023, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer ...

Yahoo | November 16, 2023

Read More 'PTGX' Stories Here

PTGX Price Returns

1-mo -9.90%
3-mo 5.75%
6-mo 81.19%
1-year 26.62%
3-year -1.66%
5-year 149.38%
YTD 13.87%
2023 110.17%
2022 -68.10%
2021 69.64%
2020 185.96%
2019 4.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!